Alejandro Ocampo, Ph.D., is a prominent figure in the field of longevity research and biotechnology. He is the Co-Founder and CEO of EPITERNA, a company dedicated to developing affordable products that can safely slow the aging process to prevent age-related diseases and extend healthy lifespan.
Dr. Ocampo’s work at the Ocampo Lab at the University of Lausanne focuses on developing novel therapies based on cellular reprogramming to address fundamental questions in aging research with translational applications to human therapies. His research views aging as a reversible epigenetic state and aims to provide biomedical solutions to prevent and reverse age-related organ failure, ultimately enabling individuals to lead healthier and longer lives.
Alejandro Ocampo has made significant contributions to the field of longevity research, particularly in epigenetic reprogramming. His work has been recognized for its potential to revolutionize how we approach aging and age-related diseases. Dr. Ocampo’s dedication to developing therapies that increase healthy lifespan underscores his commitment to advancing the field of longevity science.